First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)

Authors :: Guillermo Garcia-Manero
David A. Rizzieri
Katherine Walsh
Sue Naim
Elias Jabbour
Hagop M. Kantarjian
Pietro Taverna
Eric J. Feldman
Mohammad Azab
Wendy Stock
Gavin Choy
Scott D. Lunin
Woonbok Chung
Patricia Kropf
Karen W.L. Yee
Elizabeth A. Griffiths
Yong Hao
Casey O'Connell
Gail J. Roboz
Jean Pierre J. Issa
Source :: Journal of Clinical Oncology. 32:7030-7030
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 7030 Background: SGI-110 is a novel HMA administered as a small volume injection which results in extended decitabine exposure. We previously reported an Overall Complete Remission (OCR=CR+CRi+CRp)...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Small volume
Complete remission
Decitabine
Phases of clinical research
Myeloid leukemia
Surgery
Regimen
Hypomethylating agent
Internal medicine
Relapsed refractory
medicine
business
medicine.drug

Full Text Access

Tools